AMY-101 acetate (Cp40 acetate) is a cyclic peptide, an inhibitor of C3 Complement and an immunomodulator used in the treatment of gingivitis and periodontitis, which significantly reduces inflammation and lowers MMP-8 and MMP-9 levels.AMY-101 acetate also have a palliative effect on covid -19-induced lung inflammation/injury and SARS-COV-2-related acute kidney injury in patients with acute respiratory distress syndrome (ARDS).

AMY-101 acetate (Cp40 acetate), a compstatin-based C3 inhibitor, effectively blocks complement activation in vitro by preventing the cleavage of C3 and downstream generation of inflammatory effectors[1].

In a severe COVID-19 patient, intravenous AMY-101 acetate (5 mg/kg/day for 14 days) was well tolerated and led to rapid improvement in inflammation and respiratory function, with no renal or hepatic toxicity observed[1]. In non-human primates with naturally occurring periodontitis, local administration of AMY-101 acetate (0.1 mg/site, every 3 weeks) effectively reduced periodontal inflammation without local irritation. Daily subcutaneous administration (4 mg/kg) provided systemic protection against periodontal tissue destruction[2].